Amgen's Olpasiran Reduced Cholesterol Levels In 95% Of Patients In Mid-Stage Study By Benzinga — 10:01 AM ET 11/07/22
Amgen Inc (NASDAQ:AMGN) presented end-of-treatment data from its Phase 2 OCEAN(a)-DOSE study of olpasiran (formerly AMG 890) in adults with elevated lipoprotein levels and a history of atherosclerotic cardiovascular disease (ASCVD). These data were presented during the Nov. 6 Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions. Patients who received 75 mg or higher every 12 weeks had a 95% or greater reduction in lipoprotein levels compared to placebo at week 36. Related: Amgen Reports Q3 Higher Profit, Despite Slight Fall In Topline Growth. At these doses (75 mg or higher), more than 98% of patients achieved a lipoprotein level of 125 nmol/L or less at week 36. Overall, the rates of adverse events were similar in the olpasiran and placebo arms. The most common treatment-related adverse events were injection site reactions, primarily pain. At week 36, lipoprotein levels increased by a mean of 3.6% in the placebo arm, whereas there were substantial reductions of Lp(a) levels in all of the olpasiran arms. Placebo-adjusted mean percent reductions were 70.5% for 10 mg every 12 weeks, 97.4% for 75 mg every 12 weeks, 101.1% for 225 mg every 12 weeks, and 100.5% for 225 mg every 24 weeks. Price Action: AMGN shares are up 0.90% at $271.47 on the last check Monday.
Market Data 
Markets 
AI
